Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BGT226 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| BGT226 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BGT226 | DRUG | - |
Inclusion criteria: All patients * Histologically-confirmed, advanced solid tumors * Progressive, recurrent unresectable disease Phase II expansion part (advanced breast cancer) * Confirmed positive hormone receptor (estrogen receptor and/or progesterone receptor) or positive HER-2 expression st...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
BGT226 is an investigational small molecule being studied for the treatment of advanced solid tumors, including advanced breast cancer and Cowden syndrome. It is in Phase 1 clinical development for these oncology indications.
BGT226 is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS.
BGT226 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 1 trial has been completed.
BGT226 has been studied in one clinical trial, registered as NCT00600275. This was a Phase I/II study in adult patients with advanced solid malignancies, including advanced breast cancer, conducted in the United States, Canada, and Spain.
BGT226 is the primary name for this investigational compound. No alternative names have been established in the clinical trial record.